Is there a Need to Rush to Treatment when you Experience a Biochemical (PSA only) Prostate Cancer Recurrence?

As usual, we are confronted with a new contradiction.  It has been believed that earl hormone therapy (ADT) in men with a biochemical recurrence (PSA only) would benefit from immediate ADT.  A study released from the Harvard School of Public Health contradicts this assumption, but the study lacks follow up beyond 10 years. They evaluated [...]

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC).  This rational for conducting this trial is the lack of cross [...]